Potential for proteasome inhibition in the treatment of cancer.

@article{Adams2003PotentialFP,
  title={Potential for proteasome inhibition in the treatment of cancer.},
  author={Julian Adams},
  journal={Drug discovery today},
  year={2003},
  volume={8 7},
  pages={307-15}
}
Proteasome inhibition is a new approach to treating cancer. Proteasome inhibitors specifically induce apoptosis in cancer cells, but most proteasome inhibitors are not suitable for clinical development. Peptide boronates overcome the shortcomings of earlier generation proteasome inhibitors, and bortezomib (VELCADE; formerly PS-341) is the first peptide boronate to enter clinical trials. Preclinical studies of bortezomib have demonstrated antitumor activity in a variety of tumor types. Phase I… CONTINUE READING